Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations

Am J Med. 2023 Jan;136(1):33-41. doi: 10.1016/j.amjmed.2022.08.030. Epub 2022 Sep 20.

Abstract

Multiple myeloma is the second most common hematologic malignancy in the United States and the most common hematologic malignancy among Blacks/African Americans. Delay in diagnosis is common and has been associated with inferior disease-free survival and increased rates of myeloma-related complications. Despite a roughly 2-times higher risk of multiple myeloma, diagnostic delay appears more common, and improvements in 5-year survival rates have been slower among Blacks/African Americans than their White counterparts. When patient symptoms and basic laboratory findings are suggestive of multiple myeloma, the primary care provider should initiate extended laboratory work-up that includes serum protein electrophoresis, serum immunoglobulin free light chain assay, and serum immunofixation. Heightened awareness within high-risk populations such as Blacks/African Americans may help to eliminate racial disparities in the diagnosis and treatment of multiple myeloma.

Keywords: Diagnosis; Disparities; Early diagnosis; Multiple myeloma; Race.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Delayed Diagnosis
  • Hematologic Neoplasms*
  • Humans
  • Multiple Myeloma* / diagnosis
  • Primary Health Care